Navigation Links
XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
Date:10/29/2012

AUSTIN, Texas, Oct. 29, 2012 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes.  Results from this study continue to reinforce the role of IL-1α as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform. The Company recently announced FDA Fast Track Designation  for development of cancer associated cachexia therapy, as well as positive results from a Phase II study in psoriasis, using MABp1.

(Logo: http://photos.prnewswire.com/prnh/20121017/MM95359LOGO)

According to the Centers for Disease Control (CDC), 18.8 million people have been diagnosed with diabetes. Type 2 diabetes accounts for about 95 percent of diagnosed diabetes patients. Per the CDC, up to 74 percent of those with Type 2 diabetes are pre-insulin dependent. These patients still have a functioning pancreas and are among the approximately 13 million patients who could potentially benefit from treatment with MABp1.

The Phase II clinical study is designed to assess safety and pharmacokinetics of MABp1 in the diabetic patient population.  Patients enrolled in the study met the American Diabetes Association (ADA) diagnostic criteria for type 2 diabetes, and were diagnosed >3 months prior to screening.  The primary efficacy endpoint of glycemic control, as measured by glycated hemoglobin (HbA1c) levels, evaluates the ability of MABp1 to impro
'/>"/>

SOURCE XBiotech
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging ... China,s orthopedic instrument industry has seen rapid ... from 3.28 billion yuan in 2006 to 9.85 billion ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:7/9/2014)... Researchers from The Miriam Hospital have found that ... are also depressed have difficulty sticking to a ... true for women, and screening and brief treatment ... treatment. The study and its findings are published ... , Chronic obstructive pulmonary disease is a common ...
(Date:7/9/2014)... available in French . ... year old teens, including brain structure and function, personality, life ... will go on to develop binge drinking within the next ... other variables such as life events and a family history ... Whether or not the child had had a single ...
(Date:7/9/2014)... 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at the ... July 17 in Copenhagen, Denmark. Data from the ... transition from cognitive normality to mild cognitive impairment and ... Aging Study , established in 1980 to examine healthy ...
(Date:7/9/2014)... p>YouTube is for more than watching World Cup highlights, ... of skateboarders landing in unfortunate positions on railings. A ... Dermatology Online Journal shows that YouTube also ... with the public on topics of skin cancer and ... media is the future of how we communicate around ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
Breaking Medicine News(10 mins):Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:What drives a child to abuse alcohol? 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... "The time is right and the,wording is excellent," ... bill recognizes the God-given Right to Life of every ... end the slaughter of,innocent children.", S.3111, introduced by ... scheduled for debate in the Senate Committee on the ...
... employers also explores ROI, behaviors earning ... evaluation measures, WASHINGTON and LYNDHURST, N.J., June 26 ... and,wellness programs rose from 62 percent to 71 percent ... Also included is new data about what,programs employers reward, ...
... 26 Impliant, Inc., a developer of,novel ... announced,that it has resumed European clinical activities ... device designed to treat spinal stenosis with,or ... was,performed by the Lead Clinician of the ...
... Toronto, CANADA Adults with type 2 diabetes who ... afterward, but this can be offset by taking antioxidant ... Baycrest. , There is already growing evidence linking diabetes ... 2 diabetes are especially vulnerable to acute meal-induced memory ...
... to confer some protection against bladder cancer in mice, scientists ... had approximately 15 times as much cancer in their bladders ... findings by investigators at the University of Rochester Medical Center. ... journal Urology . , The researchers led by Jay ...
... Quarters of Fiscal 2008 ... 31, 2008 Points to Positive Fiscal 2009 Outlook for ... ... KV Pharmaceutical Company,(NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company ...
Cached Medicine News:Health News:New Survey Reveals How Much Employers Spend on Incentives for Health Management Programs 2Health News:New Survey Reveals How Much Employers Spend on Incentives for Health Management Programs 3Health News:New Survey Reveals How Much Employers Spend on Incentives for Health Management Programs 4Health News:Impliant Restarts European Clinical Activities for Patented TOPS(TM) Spine System 2Health News:Seniors with type 2 diabetes may experience memory declines immediately after eating unhealthy meal 2Health News:Seniors with type 2 diabetes may experience memory declines immediately after eating unhealthy meal 3Health News:Pregnancy may help protect against bladder cancer 2Health News:Pregnancy may help protect against bladder cancer 3Health News:KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission 2Health News:KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission 3Health News:KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission 4
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Inquire...
Medicine Products: